Compare Quest Diagnostics Inc (DGX) vs Microsoft (MSFT) Price & Performance

Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.

DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.

Microsoft (MSFT) trades at $387.66, down 0.85% with a bearish technical signal. The company demonstrates strong fundamentals with Q1 2026 EPS of $4.27 beating expectations of $4.06, continuing a trend of earnings beats. Revenue grew to $281.72B in 2025 with a robust 39.34% net income margin. Analyst consensus remains overwhelmingly bullish with 80.49% buy ratings and a $551.62 price target, representing 42% upside potential from current levels.

Microsoft's AI leadership and cloud computing strength provide significant growth catalysts, though increased capital expenditures and competitive pressures present near-term challenges. The stock's current valuation at 22.93 P/E appears reasonable given consistent earnings growth and strong cash flow generation, making it attractive for long-term investors despite technical weakness.